Evaluating Treatment Efficacy: Identifying and Managing AD Flares in Systemic Therapy Patients

Key opinion leaders in the management of dermatological disorders assess the effectiveness of systemic therapies in patients undergoing treatment.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

Now Viewing

EP: 1.Evaluating Treatment Efficacy: Identifying and Managing AD Flares in Systemic Therapy Patients

EP: 2.Composite Scores and Quality of Life: A New Standard for AD Management

EP: 3.From Trial to Practice: Applying Study Results to Real-World AD Management

EP: 4.Comprehensive Analysis: Upa Outshines Dupi Across Key Measures

EP: 5.From Clinic to Practice: Translating AD Trial Data

EP: 6.Final Thoughts: The Importance of Comparative Studies in AD

EP: 7.Improved Quality of Life: Upadacitinib's Role in Managing AD

EP: 8.Experts Delve Into Upadacitinib vs Dupilumab: Insights From LEVEL UP

Related Videos

Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies

Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children

Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists

Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability

Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis

Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma

Differentiating Between JAK Inhibitors in Clinical Practice

IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis

Clinical Attributes of IL-17 Inhibitors in Psoriasis

Laboratory Monitoring with Oral JAK Inhibitors

Related Content

Advertisement

October 9th 2024

Experts Delve Into Upadacitinib vs Dupilumab: Insights From LEVEL UP

June 25th 2020

The Cutaneous Connection: Episode 1- Cannabinoid Use in Dermatology

December 20th 2023

Reviewing New Tapinarof Data for Atopic Dermatitis Treatment

April 10th 2023

Phase 2 Trial of ADX-629 Underway for Treatment of AD

March 14th 2023

Dermatologist Shares Insights on Saving the Nail at Annual Meeting

March 10th 2023

Considering and Improving Patient Quality of Life in Dermatologic Conditions

Related Content

View More

clinicalBetween The LinesVideo Series

clinical

|

Between The Lines

|

Video Series

|

Level Up: Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to Severe Atopic Dermatitis: Results of an Open-label, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study

Advertisement

October 9th 2024

Experts Delve Into Upadacitinib vs Dupilumab: Insights From LEVEL UP

June 25th 2020

The Cutaneous Connection: Episode 1- Cannabinoid Use in Dermatology

December 20th 2023

Reviewing New Tapinarof Data for Atopic Dermatitis Treatment

April 10th 2023

Phase 2 Trial of ADX-629 Underway for Treatment of AD

March 14th 2023

Dermatologist Shares Insights on Saving the Nail at Annual Meeting

March 10th 2023

Considering and Improving Patient Quality of Life in Dermatologic Conditions